Weight loss and proteinuria
- PMID: 16929145
- DOI: 10.1159/000095332
Weight loss and proteinuria
Abstract
The level of proteinuria is one of the most determinant risk factors for the progression of proteinuric renal diseases. Several studies have shown that weight loss, either induced by low calorie diets, physical exercise, or bariatric surgery is accompanied by an important antiproteinuric effect. Reduction in proteinuria is already observed after a few weeks from the onset of weight loss and it is evident even in patients with modest weight losses. The magnitude of body weight loss and proteinuria decrease show a significant correlation. Reduction in proteinuria by weight loss has been described in obesity-induced glomerulopathy, obese diabetic patients and overweight or obese patients with different types of chronic proteinuric nephropathies. Attenuation of the obesity-induced glomerular hyperfiltration, decrease in the activity of renin-angiotensin-aldosterone system and modifications in the serum concentrations of adipocyte-derived cytokine are likely to be involved in the anti-proteinuric effect of weight loss, together with a better control of blood pressure, and improvement of serum lipid profile and insulin sensitivity.
Similar articles
-
The effect of weight loss in obesity and chronic kidney disease.Curr Hypertens Rep. 2012 Apr;14(2):170-6. doi: 10.1007/s11906-012-0247-x. Curr Hypertens Rep. 2012. PMID: 22258314 Review.
-
Therapeutic measures in proteinuric nephropathy.Kidney Int Suppl. 2005 Dec;(99):S137-41. doi: 10.1111/j.1523-1755.2005.09925.x. Kidney Int Suppl. 2005. PMID: 16336567 Review.
-
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies.Am J Kidney Dis. 2003 Feb;41(2):319-27. doi: 10.1053/ajkd.2003.50039. Am J Kidney Dis. 2003. PMID: 12552492 Clinical Trial.
-
Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.Nefrologia. 2015 Nov-Dec;35(6):554-61. doi: 10.1016/j.nefro.2015.09.008. Epub 2015 Oct 28. Nefrologia. 2015. PMID: 26519114 Clinical Trial.
-
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].Nefrologia. 2009;29(5):421-9. doi: 10.3265/Nefrologia.2009.29.5.5448.en.full. Nefrologia. 2009. PMID: 19820754 Clinical Trial. Spanish.
Cited by
-
Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.Cardiol Res Pract. 2010 Oct 7;2011:963517. doi: 10.4061/2011/963517. Cardiol Res Pract. 2010. PMID: 20953380 Free PMC article.
-
Lost and not found: randomized controlled trial of cognitive behavioral therapy for weight-loss in patients with chronic kidney disease.J Behav Med. 2025 Aug;48(4):594-604. doi: 10.1007/s10865-025-00583-w. Epub 2025 Jun 19. J Behav Med. 2025. PMID: 40537570 Free PMC article. Clinical Trial.
-
A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities.Front Endocrinol (Lausanne). 2020 Mar 10;11:91. doi: 10.3389/fendo.2020.00091. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32218769 Free PMC article.
-
Dapagliflozin's Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients.Biomedicines. 2025 May 26;13(6):1303. doi: 10.3390/biomedicines13061303. Biomedicines. 2025. PMID: 40564021 Free PMC article.
-
Association of the estimated glomerular filtration rate (eGFR) and/or proteinuria to predict the risk of initiation of dialysis in people with and without diabetes.Diabetol Int. 2022 Sep 13;14(1):86-93. doi: 10.1007/s13340-022-00603-z. eCollection 2023 Jan. Diabetol Int. 2022. PMID: 36636159 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical